Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1083-1089

  Yeo, Winnie ^a   Mo, F K F ^a   Koh, J ^a   Chan, A T C ^a   Leung, T ^a   Hui, P ^a   Chan, L ^a   Tang, A ^a   Lee, J J ^a   Mok, T S K ^a   Lai, P B S ^a   Johnson, P J ^b   Zee, B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Liver cancer; Prognostic markers; QoL

Indexed keywords

ALPHA2B INTERFERON; BILIRUBIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; HORMONE; TAMOXIFEN;

ADOLESCENT; ADULT; AGED; APPETITE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HUMAN; INFORMED CONSENT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHYSICAL PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 33745591930     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl065     Document Type: Article

References (52)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5-S16.
2. Cancer incidence and mortality in Hong Kong 1999-2000. Hong Kong Cancer Registry, Hospital Authority 2004.
3. Ho J, Wu PC, Kung TM. An autopsy study of hepatocellular carcinoma in Hong Kong. Pathology 1981; 13: 409-416.
4. Lok ASF, Lai CL, Wu PC et al. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987; 126: 492-499.
5. Pawarode A, Voravud N, Sriuranpong V et al. Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients. Am J Clin Oncol 1998; 21: 386-391.
6. Calvet X, Bruix J, Gines P et al. Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients. Hepatology 1990; 12: 753-760.
7. Okuda K. Primary liver cancers in Japan. Cancer 1980; 45: 2663-2672.
8. Lai EC, Fan ST, Lo CM et al. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 1995; 221: 291-298.
9. Johnson PJ. Hepatocellular carcinoma: Is current therapy really altering outcome? Gut 2002; 51: 459-462.
10. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001; 28: 514-520.
11. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: A systemic review of randomized controlled trials. Ann Oncol 1997; 8: 117-136.
12. CLIP Group. Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial. Lancet 1998; 352: 17-20.
13. Editorial. Quality of life and clinical trials. Lancet 1995; 346: 1-2.
14. Moinpour CM. Measuring quality of life: An emerging science. Sem Oncol 1994; 21 (Suppl 10): 48-63.
15. Danzey J, Zee B, Osaba D et al. Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical trials Group. Qual Life Res 1997; 6: 151-158.
16. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928.
17. The Cancer of the Liver Italian Program (CLIP) Investigators: A new prognostic system for hepatocellula carcinoma. Hepatology 1998; 28: 751-755.
18. Chevret S, Trinchet JC, Mathieu D et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-141.
19. Schoniger-Hekele M, Muller C, Kutilek M et al. Hepatocellular carcinoma in Central Europe: Prognostic features and survival. Gut 2001; 48: 103-109.
20. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
21. Leung T, Tang A, Zee B. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system. Cancer 2002; 94: 1760-1769.
22. Vauthey J-N, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20: 1527-1536.
23. Tateishi R, Yoshida H, Shiina S. Proposal of a new prognostic model for hepatocellular carcinoma: An analysis of 403 patients. Gut 2005; 54: 419-425.
24. Yeo W, Zee B, Leung WT et al. A phase III study of adriamycin (A) versus cisplatin (P)/interferonα-2b (I)/adriamycin (A)/fluorouracil (F) combination chemotherapy (PIAF) for inoperable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2004; 23: 319.
25. Chow PKH, Tai BC, Tan CK et al. High dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002; 36: 1221-1226.
26. Aaronson NK, Ahmedzai Bergman B et al. The European Organization of Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
27. Fayers P, Aaronson NK, Bjordal K et al. EORTC QLQ-C30 Scoring Manual, 2nd edition. Belgium: EORTC Data Center 1999.
28. Sobin LH, Wittekind C (eds). TNM Classification of Malignant Tumors, 5th edition. Union Internationale Centre le Cancer. New York: John Wiley & Sons 1997.
29. Dancey J, Zee B, Osoba D et al. for the National Cancer Institute of Canada Clinical Trials Group. Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res 1997; 6: 151-158.
30. Ringdal GI, Ringdal K, Kvinnsland S et al. Quality of life of cancer patients with different prognosis. Qual Life Res 1994; 3: 143-154.
31. Ringdal GI, Gotestam KG, Kaasa S et al. Prognostic factors and survival in a heterogeneous sample of cancer patients. Br J Cancer 1996; 73: 1594-1599.
32. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997; 33: 1025-1030.
33. Coates A, Forbes J, Simes RJ. Prognostic value of performance status and quality of life scores during chemotherapy for advanced breast cancer. The Australian New Zealand Breast Cancer Trials Group. J Clin Onol 1993; 11: 2050.
34. Kramer JA, Curran D, Piccart M et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 2000; 36: 1498-1506.
35. Efficace F, Biganzoli L, Piccart M et al. Baseline health-related quality of life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 2004; 40: 1021-1030.
36. Langendijk H, Aaronson NK, de Jong JMA et al. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 2000; 55: 19-25.
37. Montazeri A, Milroy R, Hole D et al. Quality of life in lung cancer patients as an important prognostic factor. Lung Cancer 2001; 31: 233-240.
38. Herndon JE, Fleishman S, Kornblith AN et al. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 1999; 85: 333-340.
39. Dharma-Wardene M, Au HJ, Hanson J et al. Baseline FACT-G score is a predictor of survival for advanced lung cancer. Quality of Life Reseach 2004; 13: 1209-1216.
40. Blazeby JM, Brookes ST, Alderson D. The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 2001; 49: 227-230.
41. Fang FM, Tsai WL, Chiu H et al. Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int J Radiation Biol Phys 2004; 58: 1394-1404.
42. Chau I, Norman AR, Cunningham D et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trails using individual patients Data. J Clin Oncol 2004; 22: 2395-2403.
43. de Graeff A, de Leeuw JRJ, Ros WJG et al. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 2001; 37: 332-339.
44. Ramsey SD, Anderson MR, Etzioni R et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 39: 1294-1303.
45. Coates A, Thomson D, McLeod GR et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993; 29A: 1731-1734.
46. Wisloff F, Hjorth M et al for the Nordic Myeloma Study Group. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Br J Haematol 1997; 97: 29-37.
47. Kornblith AB, Thaler HT, Wong G et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995; 59: 231-242.
48. Langendijk H, Aaronson NK, ten Velde GP et al. Pretreatment quality of life in patients with glioblastoma multiforme. Oncol Nurs Forum 1999; 26: 921-925.
49. Blazeby JM, Williams MH, Alderson D, Farndon JR. Observer variation in assessment of quality of life in patients with oesophageal cancer. Br J Surg 1995; 82: 1200-1203.
50. Wilson KA, Dowling AJ, Abdolell M, Tannock IF. Perception of quality of life by patients, partners and treating physicians. Qual Life Res 2000; 9: 1041-1052.
51. Heffernan N, Cella D, Webster K et al. Measuring health-related quality of life in patients with hepatobiliary cancers: The functional assessment of cancer therapy-hepatobiliary questionnaire. Clin Oncol 2002; 20: 2229-2239.
52. Blazeby JM, Currie E, Zee BC et al. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer 2004; 40: 2439-2444.